ID: h-SDA-2026-04-26-gap-20260426-001521-07-
Hypothesis
Soluble LRP1 Fragments Serve as Blood-Based Indicators of Impaired Aβ Efflux and BBB Transporter Dysfunction
LRP1 at brain microvascular endothelium mediates Aβ export from CNS to periphery.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
LRP1 at brain microvascular endothelium mediates Aβ export from CNS to periphery. AD-associated inflammation activates ADAM10/17-mediated proteolytic shedding of LRP1's extracellular domain (sLRP1), reducing endothelial Aβ clearance capacity. However, LRP1 is ubiquitously expressed (liver, lung, macrophages), and peripheral sources dominate plasma sLRP1, making brain-specific interpretation unreliable.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["AD-associated<br/>Inflammation"]
B["ADAM10/17-mediated<br/>LRP1 Shedding"]
C["sLRP1<br/>Fragment Release"]
D["A beta Efflux<br/>Impairment"]
E["Brain A beta<br/>Accumulation"]
F["BBB Transporter<br/>Dysfunction"]
G["Peripheral Blood<br/>sLRP1 Signal"]
A --> B
B --> C
C --> D
D --> E
C --> G
E --> F
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style C fill:#e65100,stroke:#ffab91,color:#ffab91
style G fill:#e65100,stroke:#ffab91,color:#ffab91⚖️ Evidence
⚖️ Evidence Matrix3 supports3 contradicts
Supports
sLRP1 levels in plasma inversely correlate with brain Aβ burden and cognitive function
Supports
ADAM10/17 responsible for LRP1 ectodomain shedding in response to inflammatory stimuli
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LRP1
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for LRP1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LRP1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1247
Events (7d)
1
Price History
▲2.1%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we stratify early-stage AD patients by degree of BBB dysfunction (using dynamic contrast-enhanced MRI permeability metrics) THEN plasma sLRP1 fragment concentrations will be significantly elevated | Plasma sLRP1 fragment levels (measured by ELISA targeting the extracellular domain) will be positively correlated with BBB permeability (Ktrans values) in AD pa | — no observation — | pending | 0.65 |
| IF we chronically inhibit ADAM10/17 activity (via pharmaceutical blockade or genetic knockdown) in 5xFAD transgenic mice starting at 3 months of age THEN brain microvascular endothelial sLRP1 protein | ADAM10/17 inhibition will reduce proteolytic shedding of LRP1 at the brain endothelium, preserving full-length LRP1 function and enhancing Aβ efflux capacity, a | — no observation — | pending | 0.58 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF we stratify early-stage AD patients by degree of BBB dysfunction (using dynamic contrast-enhanced MRI permeability metrics) THEN plasma sLRP1 fragment concentrations will be significantly elevated (≥30% increase) in the high BBB dysfunction stratum compared to age-matched controls without BBB imp
Predicted outcome: Plasma sLRP1 fragment levels (measured by ELISA targeting the extracellular domain) will be positively correlated with BBB permeability (Ktrans values
Falsification: No significant correlation between plasma sLRP1 and MRI-measured BBB permeability; or sLRP1 levels are indistinguishable between AD patients with high vs. low BBB dysfunction, indicating peripheral so
pendingconf 58%
IF we chronically inhibit ADAM10/17 activity (via pharmaceutical blockade or genetic knockdown) in 5xFAD transgenic mice starting at 3 months of age THEN brain microvascular endothelial sLRP1 protein levels will increase (≥40%) and cerebral Aβ40/42 accumulation will decrease (≥25%) compared to vehic
Predicted outcome: ADAM10/17 inhibition will reduce proteolytic shedding of LRP1 at the brain endothelium, preserving full-length LRP1 function and enhancing Aβ efflux c
Falsification: sLRP1 fragment levels decrease as expected with ADAM10/17 inhibition but Aβ burden shows no significant reduction (p>0.05), indicating sLRP1 shedding is not causally linked to impaired Aβ clearance, o
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.